۲. J		icas remained Dr		<u>odeitiili</u>		812T								and a subscription of the
													6	
		No.			<u>Main Co</u>	mmittee						2.2	/23.3.84	yrrrrraidd a de Werold.
		рь 3070)/0007										<u>rant of</u> .	C
		<u><u>Coy</u>.</u>			1. cl	arifíca	tior. wa	is prov:	Lded or	n certai	.n aspe	on that: cts of t	he	*By Jacobio Allino 1994
		Speywoo Product	d Labs	Ltd	collect changes Product	ion; in made to Specif	itial p o the m ication	orocess manufac ms over	ing; si turing; the pe	cerilisa (control eriod of	tion o proce time	the prod	c bags; Finishe uct has	
		Hya te:	C		polyele	ctrolyt	e; and	on the	in pro	ocess le	vels o	used in f extrac	tables,	Jan Contract and American
		Therape	<u>utic Cl</u>	ass_	used in	the as	say of	the pr	oduct,	that is	both	III star the "in- ts Ltd.,	house"	
		Porcine Product			along w		ails of	t how t	hese a	nd stand		were pro ability	ovided tests on	
		Active Porcine VIII:C	<u>Constit</u> Factor		4, th justifi		s appl:	ied to	the fo	llowing	were C	ightened	l or	
					11	1) P1 1) Re	atelet	polyet	ating a	y, activity glycol,				
	-				Remark	.v) Al		U U						
						the ev ee cons			u <u>ct L</u> i	cence be	eing gr	anted t	ie	
					pa	spectio	n repoi 11 refei	rts Ero rence t	m the o the	factory	and th	i satisf le abbati posed b	oir, with	
					1.	2 the	e Compan	ny shou	ld be	encoura; studíes		set up iltor th	e	
						ng-term	ı safet;	y of Hy	ate: C	,		applied		an a
					sd o to	atches o bulks ne Secre	of the p and in stariat	product -proces with d	and s s samp etails	hould i les. T of the	nclude he comp assay	the pro any sho procedu	vision uld suppl res agree	
						ontrol.		ai inst	litute	01 8101	ogicai	Standar		
							·							
												M	/ITN6406	3013 (

WITN6406013_0001

APPENDIX A

÷

No .	SUB-COMMITTEE ON BIOLOGICAL PRODUCTS 7 MARCH 1984					
PL/3070/0007	RECOMMENDATION					
<u>Coy.</u>	On the evidence before them the Sub-Committee, on grounds of safety and quality, were unable to recommend the grant of a Product Licence for this product.					
Speywood Laboratories Ltd	The Sub-Committee considered that:					
Product. Hyate: C	1. there was insufficient evidence of safety in long- term use for the propylamine extractables present in the product,					
<u>Therapeutic Class</u>	2. the Company should justify the aluminium levels in the finished product and demonstrate that these levels do not provide a toxic hazard in clinical use,					
Blood Product	3. clarification should be provided on certain aspects of the manufacturing process, with particular reference					
<u>Active Constituent</u> Porcine Factor VIII:C	to: blood collection; initial processing; sterilisa- tion of plastic bags; changes made to the manufacturing/ control processes and Finished Product Specifications over the period of time the product has been in clinical use; the choice of molar ratio used in the polyelectro- lyte; and on the in process levels of extractables,					
	4. full details should be provided of the Factor VIII standards used in the assay of the product, that is both the "in-house" standard and that supplied by Diagnostic Reagents Ltd.,					
	5. data from the accelerated stability study should be provided along with details of how these and standard stability tests on an on-going basis will be undertaken,					
	6. justification should be provided for the limits applied to:					
	 i) Factor VIII:C activity, ii) Platelet aggregating activity, iii) Residual polyethylene glycol, iv) Aluminium 					
	<u>Remarks</u>					
	1. in the event of a Product Licence being granted the Sub-Committee considered that:					
	1.1 the licence should be conditional on satis- factory inspection reports from the factory and the abbatoir, with particular reference to the use of the proposed blood collection technology,					
	1.2 the Company should be encouraged to set up post-marketing surveillance studies to monitor the long-term safety of Hyate: C,					

<u>No.</u> PL/3070/0007 <u>Coy.</u>	1.3 a full stop-on-sale order should be applied to all batches of the product, to include the provision of bulks and in-process samples. The company should supply the Secretariat with details of the assay procedures agreed with the National Institute of Biological Standards and Control.
Speywood Laboratories Ltd	Remark to SEAR
<u>Product</u> Hyate: C	2. the Sub-Committee would look more favourably on an application for a Clinical Trial Certificate, provided it was recognised that long term toxicity data would need need to be available by the PL stage.
Therapeutic Class	
Blood Product	
Active Constituent Porcine Factor VIII:C	
Forcine Factor VIII.C	

WITN6406013_0003